This site is intended for health professionals only

Generic challenge over chewable Pill

teaser

A drug company is facing a challenge over its chewable contraceptive pill.

US firm Warner Chilcott has received a paragraph IV certification notice from another US company, Barr Laboratories.

Barr filed an abbreviated new drug application (ANDA) for a generic version of Femcon Fe® (norethindrone), the patent for which expires in 2019.

Warner Chilcott, based in New Jersey, is a speciality company focused on manufacturing, marketing and selling branded prescription products in women’s healthcare and dermatology in the US.

Barr, based in New York, is a global firm engaged in developing both generic and proprietary pharmaceuticals.

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Paragraph IV certification begins a process in which the question of whether a patent is valid or will be infringed by the proposed generic product may be studied by the courts prior to the patent’s expiry.

When an ANDA applicant files a paragraph IV for a listed patent, the applicant must also notify the patent owner.

The notice must include a statement of the factual and legal basis for the ANDA applicant’s opinion that the patent is not valid, or will not be infringed by the generic.

A statement from Warner Chilcott said: “The company is reviewing the detail of the paragraph IV notice from Barr, and continues to have full confidence in its intellectual property protecting Femcon Fe.”

Copyright © PA Business 2007

Warner Chilcott: www.warnerchilcott.com/index.php

 






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x